Genmab A/S
http://www.genmab.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Genmab A/S
Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh
Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.
BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024
As COVID-19 vaccine sales decline, the company is investing billions in a diverse oncology pipeline including antibody drug conjugates, immunotherapy and cancer vaccines
China Biotech Podcast: AACR, BIOSECURE European Perspectives
Guest Andrew McConaghie from Scrip's UK team joins Brian Yang and Dexter Yan to discuss AACR highlights from Chinese biotechs, European perspectives on the proposed US BIOSECURE Act, two recent acquisitions and Boehringer Ingelheim's recent quarterly results.
Roche Steals A March In B-cell Lymphoma
New data on Columvi could allow the bispecific’s use as an earlier treatment, giving it a three-year head start on AbbVie and Genmab’s Epkinly.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice